Guard Therapeutics International AB Total Liabilities
Guard Therapeutics International AB total liabilities. Based on the latest financial reports, Guard Therapeutics International AB (GUARD) has total liabilities worth Skr15.24 Million SEK (≈ $1.64 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GUARD cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Guard Therapeutics International AB (2008–2024)
Total liabilities of Guard Therapeutics International AB from 2008 to 2024. This chart illustrates how Guard Therapeutics International AB's total liabilities have evolved over time, based on quarterly financial data.
Guard Therapeutics International AB Competitors by Total Liabilities
The table below lists competitors of Guard Therapeutics International AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Banzai International, Inc.
NASDAQ:PARA
|
USA | $19.07 Million |
|
Hanil Vacuum Co. Ltd
KQ:123840
|
Korea | ₩24.65 Billion |
|
Airtouch Solar Ltd
TA:ARTS
|
Israel | ILA24.46 Million |
|
CHRISTINA LAKE CANNABIS
F:CLB
|
Germany | €9.97 Million |
|
De La Rue PLC
LSE:DLAR
|
UK | GBX298.90 Million |
|
Bilici Yatirim Sanayi ve Ticaret AS
IS:BLCYT
|
Turkey | TL910.61 Million |
|
Vaxtex Cotfab Limited
NSE:VCL
|
India | Rs143.82 Million |
|
Ecobuilt Holdings Bhd
KLSE:0059
|
Malaysia | RM89.28 Million |
Liability Composition Analysis (2008–2024)
This chart breaks down Guard Therapeutics International AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Guard Therapeutics International AB.
Liquidity & Leverage Metrics
Guard Therapeutics International AB Total Liabilities Ratios Explained
Guard Therapeutics International AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 4.79 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guard Therapeutics International AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guard Therapeutics International AB (2008–2024)
The table below shows the annual total liabilities of Guard Therapeutics International AB from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr17.77 Million ≈ $1.91 Million |
-3.89% |
| 2023-12-31 | Skr18.49 Million ≈ $1.99 Million |
-26.74% |
| 2022-12-31 | Skr25.24 Million ≈ $2.72 Million |
+72.20% |
| 2021-12-31 | Skr14.66 Million ≈ $1.58 Million |
+27.08% |
| 2020-12-31 | Skr11.54 Million ≈ $1.24 Million |
+4.02% |
| 2019-12-31 | Skr11.09 Million ≈ $1.19 Million |
-63.30% |
| 2018-12-31 | Skr30.21 Million ≈ $3.25 Million |
+158.65% |
| 2017-12-31 | Skr11.68 Million ≈ $1.26 Million |
-3.71% |
| 2016-12-31 | Skr12.13 Million ≈ $1.31 Million |
+34.74% |
| 2015-12-31 | Skr9.00 Million ≈ $968.97K |
+57.61% |
| 2014-12-31 | Skr5.71 Million ≈ $614.81K |
-73.74% |
| 2013-12-31 | Skr21.75 Million ≈ $2.34 Million |
+26.15% |
| 2012-12-31 | Skr17.25 Million ≈ $1.86 Million |
+204.79% |
| 2011-12-31 | Skr5.66 Million ≈ $608.90K |
+549.00% |
| 2010-12-31 | Skr871.82K ≈ $93.82K |
+191.58% |
| 2008-12-31 | Skr299.00K ≈ $32.18K |
-- |
About Guard Therapeutics International AB
Guard Therapeutics International AB (publ), a clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden. Its pipeline products include RMC-035, an intact therapeutic A1M protein, that is in Phase 2b clinical trial for kidney protection with open-heart surgery; in Phase 2a clinical trial for kidney transplantation; and is in preclinical trial to tre… Read more